Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada

Abstract Background Dupilumab, omalizumab, and mepolizumab are the three biologics currently approved for use in CRSwNP in Canada. Despite evidence of efficacy, their cost-effectiveness, which is a key factor influencing prescribing patterns, has not yet been compared to each other. Methods A cost-e...

Full description

Bibliographic Details

Published in:	Allergy, Asthma & Clinical Immunology
Main Authors:	Michael Yong, Keshinisuthan Kirubalingam, Martin Y. Desrosiers, Shaun J. Kilty, Andrew Thamboo
Format:	Article
Language:	English
Published:	BMC 2023-10-01
Subjects:	Cost-effectiveness Biologics Chronic Rhinosinusitis Nasal Polyps
Online Access:	https://doi.org/10.1186/s13223-023-00823-1